Testosterone Replacement Therapy and Cardiovascular Risk: A Review.

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Pharmacology

Background:

• Recent reports suggest testosterone replacement therapy (TRT) may increase cardiovascular (CV) risk.
• The FDA advises TRT is approved only for hypogonadism, not aging-related low testosterone.
• Concerns exist regarding the CV safety of TRT.

Purpose of the Study:

• To review and analyze available evidence on the association between TRT and CV risk.
• To critically evaluate data from randomized controlled trials and observational studies.
• To determine if TRT causally increases adverse CV events.

Main Methods:

• Systematic review and meta-analysis of scientific literature.
• Inclusion of data from randomized controlled studies.
• Scrutiny of observational and pharmacoepidemiological investigations.

Main Results:

• Meta-analyzed data do not support a causal link between TRT and adverse CV events.
• This finding holds true when hypogonadism is correctly diagnosed and TRT is properly administered.
• Elevated hematocrit is the most frequent adverse event, necessitating regular monitoring.

Conclusions:

• TRT is not associated with increased cardiovascular risk in properly diagnosed and treated hypogonadism.
• Close monitoring of hematocrit levels is essential during TRT to mitigate risks.
• The study provides evidence against a causal role of TRT in adverse CV events.